N Figure 2. The results were interpreted by the scientific committee and permitted the improvement from the suggestions. An independent committee (Appendix 1) validated the final version of recommendations (EH, CL, PT). Two members on the PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21310556 scientific committee elaborated the final document (LS, PML).Forty-two professionals completed the questionnaire (Appendix two), representing 79 of these contacted. The reasons for the non-participation in the remaining 11 professionals had been that they had either also a lot consultancy work or insufficient availability to reply inside the time limits. The sociodemographic information and skilled activities in the experts’ panel are presented in Table three.Target population IndicationsIndications for the usage of LAI FGA and LAI SGA are summarized in Table four. The relevant question from the survey using the experts’ answers are given in Figure 2.Figure 2 Graphic results in the query about indications for use of LAI.Llorca et al. BMC Psychiatry 2013, 13:340 http:www.biomedcentral.com1471-244X13Page 5 ofTable 3 Socio-demographic data and expert activities in the experts’ panel (N = 42 experts)Age (years) N Imply SD Min; Max Median Years of practice N Mean SD Min; Max Median Remedy of sufferers in outpatients N Mean SD Min; Max Median Treatment of individuals in hospital N Mean SD Min; Max Median Throughout the final five years, within the field of LAI FGALAI SGA N Clinical activity Study projects Publications Communications N Conferences Congress Teaching 42 46.81 9.82 31; 63 46 41 17.29 10.20 2; 37 16 41 68.90 22.43 25; one hundred 75 41 31.ten 22.43 0; 75 25 42 42 (100.0 ) 18 (42.9 ) 12 (28.six ) 36 22 (61.1 ) 24 (66.7 ) 22 (61.1 )They may be contraindicated in organic mental problems with behavioural disorders (Alzheimer’s disease, vascular dementia). LAI FGA are advisable (in monotherapy or combination): as 2nd line therapy in schizophrenia, delusional disorder, schizoaffective disorder and personality problems. They’re contraindicated in recurrent depressive disorder and in organic mental issues with behavioural problems.Most acceptable introduction period through the illnessThe most acceptable period for the introduction of LAI FGA and SGA are summarized Table 5. Only LAI SGA are deemed as a therapeutic alternative through the initial phase of schizophrenic illness: They may be recommended in the first psychotic episode. Their introduction in the first recurrent psychotic episode can also be advisable (if the patient was not treated with an LAI antipsychotic). LAI FGA aren’t recommended for the duration of the early course of schizophrenia (i.e. inside a patient who has been newly diagnosed with schizophrenia and who has had no earlier antipsychotic therapy). They has to be employed as maintenance therapy through the long-term evolution on the illness in the case of efficacy on the MedChemExpress 4-IBP corresponding oral formulation and when the benefitrisk ratio is regarded as satisfactory.Selection criteria for an LAI FGA or LAI SGA in accordance with the clinical qualities of patientLAI SGA are advised (in monotherapy or combination): as 1st line remedy in schizophrenia, delusional disorder and schizoaffective disorder. as 2nd line remedy in bipolar disorder and character issues.Table four LAI FGA and LAI SGA indications in accordance with the DSM-IV-TR criteriaLAI FGA 1st line remedy Schizophrenia Delusional disorder Schizoaffective disorder 2nd line treatment Schizophrenia Delusional disorder Schizoaffective disorder Character disorder Bipolar disorder.